C21 in COVID-19 [COVID-19]
Research type
Research Study
Full title
A randomised, double-blind, placebo-controlled, phase 2 trial investigating the safety and efficacy of C21 in hospitalised subjects with COVID-19 infection not requiring mechanical ventilation
IRAS ID
282495
Contact name
Joanna Porter
Contact email
Sponsor organisation
Vicore Pharma AB
Eudract number
2020-001502-38
Duration of Study in the UK
0 years, 3 months, 1 days
Research summary
This is a randomized, double blind, placebo controlled, Phase 2 trial investigating the safety and efficacy of C21 in hospitalized subjects with COVID-19 infection not requiring mechanical ventilation. \n\nCurrently, there is no effective or approved treatment for COVID-19 infection in the UK. Several clinical trials are ongoing and investigating e. g. antiviral and immunomodulatory agents in the search for urgent, safe, and effective treatment of COVID-19 infection as well as vaccines for prophylactic treatment of COVID-19 infection (WHO). At present, 260 trials investigating COVID-19 are listed on the website www.clinicaltrials.gov.
REC name
East of England - Cambridge Central Research Ethics Committee
REC reference
20/EE/0130
Date of REC Opinion
6 May 2020
REC opinion
Further Information Favourable Opinion